Adaptimmune is committed to treating the most challenging solid tumors using a proprietary cell therapy platform that harnesses a patient's cells to combat their cancer.
Using a personalized approach that has the potential to radically improve the patient experience.
We use cell therapy, a promising yet complex area of science, to engineer a person’s own cells to fight cancer.
A future where a single infusion could reshape cancer care.
We are a fully integrated company on the verge of a new era. With our first BLA submitted to the FDA, we are aiming to commercialize the first engineered T-cell therapy in solid tumors to help improve cancer treatment.
Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy